乳腺癌患者糖酵解相关的高风险基因预后分析
Prognosis Analysis of Glycolysis Related High-Risk Genes in Patients with Breast Cancer
DOI: 10.12677/ACM.2023.1371653, PDF,   
作者: 肖 燕, 李 静*:青岛大学附属医院检验科,山东 青岛;肖懿洋:青岛大学附属医院康复医学科,山东 青岛;张佳玉:青岛大学附属医院血液科,山东 青岛;邓志莹:青岛大学附属医院老年医学科,山东 青岛;张佳琪:山东大学齐鲁医院德州医院输血科,山东 德州
关键词: 乳腺肿瘤糖酵解生物信息学预后分析Breast Cancer Glycolysis Bioinformatics Prognostic Analysis
摘要: 目的:利用生物信息学筛选乳腺癌糖酵解相关的高风险基因,为乳腺癌寻找预后标志物或潜在治疗靶点。方法:通过TCGA数据库,下载乳腺肿瘤患者的转录组数据和临床数据,利用GSEA和R4.0.3对该数据集进行基因富集及差异分析。将得到的差异性基因与临床数据合并,构建糖酵解预后模型并进行模型验证。最后用GEPIA数据库对预测的显著差异的糖酵解基因做单基因生存分析,并用GEO数据库中三阴性乳腺癌数据集进行验证。结果:从TCGA数据库收集到乳腺肿瘤患者的转录组数据包括正常组织文件111个,肿瘤组织文件1053个。富集分析筛选后得到正常组和肿瘤组差异基因256个,其中显著差异的糖酵解基因5个,其表达量与患者预后呈负相关,与GEPIA单基因预后分析一致。GEO数据库三阴性乳腺癌数据集进行验证,证实基因PGK1、SDC1、PGK1为乳腺癌的高风险基因。结论:通过生物信息学分析发现糖酵解基因PGK1、SDC1、PGK1可能作为乳腺癌的预后指标,为乳腺肿瘤特别是三阴性乳腺癌的诊断及治疗提供了新的方向。
Abstract: Objective: Using bioinformatics to investigate high-risk genes of breast cancer (BC) glycolysis to find prognostic markers or potential therapeutic targets. Methods: The mRNA expression profiles and clinical information of patients with BC were obtained from The Cancer Genome Atlas (TCGA) data-base. Glycolysis-related differential genes were obtained by Gene Set Enrichment Analysis (GSEA) and R4.0.3, which be used to construct the prognosis model. We verified the accuracy of the model. Finally, we performed a single gene survival analysis using Gene Expression Profiling Interactive Analysis (GEPIA), and we used the triple negative breast cancer (TNBC) dataset from the GEO data-base to verify the prognosis of high-risk genes. Results: Profiling of mRNA expression was carried out in samples of patients with TCGA BC (tumour = 1053, nomal = 111). GSEA has been undertaken to get differential genes 256, among them, 5 genes were significantly different and they are a nega-tive correlation with the prognosis of BC patients. Survival analysis of five genes was performed us-ing the GEPIA database, and the results were consistent with the prediction. The TNBC dataset from GEO database verified that genes PGK1, SDC1 and PGK1 were high-risk genes for BC. Conclusion: Glycolytic genes PGK1, SDC1 and PGK1 may be used as prognostic indicators of breast tumors, which provides a new direction for the diagnosis and treatment of BC, especially TNBC.
文章引用:肖燕, 肖懿洋, 张佳玉, 邓志莹, 张佳琪, 李静. 乳腺癌患者糖酵解相关的高风险基因预后分析[J]. 临床医学进展, 2023, 13(7): 11794-11803. https://doi.org/10.12677/ACM.2023.1371653

参考文献

[1] Sung, H., et al. (2019) Global Patterns in Excess Body Weight and the Associated Cancer Burden. CA: A Cancer Journal for Clinicians, 69, 88-112.
[2] Hagan, C.R. and Lange, C.A. (2014) Molecular Determinants of Context-Dependent Progesterone Receptor Action in Breast Cancer. BMC Medicine, 12, Article No. 32.
[3] Daniel, A.R., et al. (2015) Progesterone Receptor-B Enhances Estrogen Responsiveness of Breast Cancer Cells via Scaffolding PELP1- and Estro-gen Receptor-Containing Transcription Complexes. Oncogene, 34, 506-515. [Google Scholar] [CrossRef] [PubMed]
[4] Knutson, T.P. and Lange, C.A. (2014) Tracking Progesterone Recep-tor-Mediated Actions in Breast Cancer. Pharmacology & Therapeutics, 142, 114-125. [Google Scholar] [CrossRef] [PubMed]
[5] Chavez, K.J., Garimella, S.V. and Lipkowitz, S. (2010) Tri-ple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. Breast Disease, 32, 35-48. [Google Scholar] [CrossRef
[6] Anders, C.K. and Carey, L.A. (2009) Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. Clinical Breast Cancer, 9, S73-S81. [Google Scholar] [CrossRef
[7] Spinelli, J.B. and Haigis, M.C. (2018) The Multifaceted Contribu-tions of Mitochondria to Cellular Metabolism. Nature Cell Biology, 20, 745-754. [Google Scholar] [CrossRef] [PubMed]
[8] Cluntun, A.A., Lukey, M.J., Cerione, R.A. and Locasale, J.W. (2017) Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends in Cancer, 3, 169-180. [Google Scholar] [CrossRef] [PubMed]
[9] DePeaux, K. and Delgoffe, G.M. (2021) Metabolic Barriers to Cancer Immunotherapy. Nature Reviews Immunology, 21, 785-797. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, X., et al. (2019) Adjudin Synergizes with Paclitaxel and Inhibits Cell Growth and Metastasis by Regulating the Sirtuin 3-Forkhead Box O3a Axis in Human Small-Cell Lung Cancer. Thoracic Cancer, 10, 642-658. [Google Scholar] [CrossRef] [PubMed]
[11] Mao, L., et al. (2018) Berberine Decelerates Glucose Metabolism via Suppression of mTOR-Dependent HIF-1α Protein Synthesis in Colon Cancer Cells. Oncology Reports, 39, 2436-2442. [Google Scholar] [CrossRef] [PubMed]
[12] Warburg, O. (1956) On the Origin of Cancer Cells. Science, 123, 309-314. [Google Scholar] [CrossRef] [PubMed]
[13] Guo, D., et al. (2022) Aerobic Glycolysis Promotes Tumor Immune Evasion by Hexokinase2-Mediated Phosphorylation of IκBα. Cell Metabolism, 34, 1312-1324.E6. [Google Scholar] [CrossRef] [PubMed]
[14] Wu, C., et al. (2019) Integrative Analysis of DiseaseLand Omics Database for Disease Signatures and Treatments: A Bipolar Case Study. Frontiers in Genetics, 10, Article 396. [Google Scholar] [CrossRef] [PubMed]
[15] McCarrey, J.R. and Thomas, K. (1987) Human Testis-Specific PGK Gene Lacks Introns and Possesses Characteristics of a Processed Gene. Nature, 326, 501-505. [Google Scholar] [CrossRef] [PubMed]
[16] Chiarelli, L.R., et al. (2012) Molecular Insights on Pathogenic Effects of Mutations Causing Phosphoglycerate Kinase Deficiency. PLOS ONE, 7, e32065. [Google Scholar] [CrossRef] [PubMed]
[17] Hu, H., et al. (2017) Acetylation of PGK1 Promotes Liver Can-cer Cell Proliferation and Tumorigenesis. Hepatology, 65, 515-528. [Google Scholar] [CrossRef] [PubMed]
[18] Li, X., Zheng, Y. and Lu, Z. (2016) PGK1 Is a New Member of the Protein Kinome. Cell Cycle, 15, 1803-1804. [Google Scholar] [CrossRef] [PubMed]
[19] Daly, E.B., Wind, T., Jiang, X.M., Sun, L. and Hogg, P.J. (2004) Secretion of Phosphoglycerate Kinase from Tumour Cells Is Controlled by Oxygen-Sensing Hydroxylases. Bio-chimica et Biophysica Acta, 1691, 17-22. [Google Scholar] [CrossRef] [PubMed]
[20] Piperigkou, Z., Mohr, B., Karamanos, N. and Gotte, M. (2016) Shed Proteoglycans in Tumor Stroma. Cell and Tissue Research, 365, 643-655. [Google Scholar] [CrossRef] [PubMed]
[21] Palaiologou, M., Delladetsima, I. and Tiniakos, D. (2014) CD138 (Syndecan-1) Expression in Health and Disease. Histology and Histopathology, 29, 177-189.
[22] Gotte, M., et al. (2006) Predictive Value of Syndecan-1 Expression for the Response to Neoadjuvant Chemotherapy of Primary Breast Cancer. Anticancer Research, 26, 621-627.
[23] Ibrahim, S.A., et al. (2017) Syndecan-1 Is a Novel Molecular Marker for Triple Negative Inflammatory Breast Cancer and Modulates the Cancer Stem Cell Phenotype via the IL-6/STAT3, Notch and EGFR Signaling Pathways. Molecular Cancer, 16, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[24] Baba, F., et al. (2006) Syndecan-1 and Syndecan-4 Are Overex-pressed in an Estrogen Receptor-Negative, Highly Proliferative Breast Carcinoma Subtype. Breast Cancer Research and Treatment, 98, 91-98. [Google Scholar] [CrossRef] [PubMed]
[25] Barbareschi, M., et al. (2003) High Syndecan-1 Expression in Breast Carcinoma Is Related to an Aggressive Phenotype and to Poorer Prognosis. Cancer, 98, 474-483. [Google Scholar] [CrossRef] [PubMed]
[26] Scholl, U.I., Stolting, G. and Nelson-Williams, C. (2015) Recurrent Gain of Function Mutation in Calcium Channel CACNA1H Causes Early-Onset Hypertension with Primary Aldosteronism. eLife, 4, e06315. [Google Scholar] [CrossRef
[27] Viet, C.T., et al. (2021) The REASON Score: An Epigenetic and Clinicopathologic Score to Predict Risk of Poor Survival in Patients with Early Stage Oral Squamous Cell Carcinoma. Biomarker Research, 9, Article No. 42. [Google Scholar] [CrossRef] [PubMed]
[28] Loiodice, I., et al. (2004) The Entire Nup107-160 Complex, In-cluding Three New Members, Is Targeted as one Entity to Kinetochores in Mitosis. Molecular Biology of the Cell, 15, 3005-3508. [Google Scholar] [CrossRef] [PubMed]
[29] Wynn, T.A. (2003) IL-13 Effector Functions. Annual Review of Immunology, 21, 425-456. [Google Scholar] [CrossRef] [PubMed]
[30] Kioi, M., Seetharam, S. and Puri, R.K. (2008) Targeting IL-13Rα2-Positive Cancer with a Novel Recombinant Immunotoxin Composed of a Single-Chain Antibody and Mutated Pseudomonas Exotoxin. Molecular Cancer Therapeutics, 7, 1579-1587. [Google Scholar] [CrossRef
[31] Han, J. and Puri, R.K. (2018) Analysis of the Cancer Ge-nome Atlas (TCGA) Database Identifies an Inverse Relationship between Interleukin-13 Receptor α1 and α2 Gene Ex-pression and Poor Prognosis and Drug Resistance in Subjects with Glioblastoma Multiforme. Journal of Neu-ro-Oncology, 136, 463-474. [Google Scholar] [CrossRef] [PubMed]
[32] Zhou, W., et al. (2020) A Glycoly-sis-Related Gene Pairs Signature Predicts Prognosis in Patients with Hepatocellular Carcinoma. PeerJ, 8, e9944. [Google Scholar] [CrossRef] [PubMed]
[33] Jiang, F., Wu, C., Wang, M., Wei, K. and Wang, J. (2021) Identification of Novel Cell Glycolysis Related Gene Signature Predicting Survival in Patients with Breast Cancer. Scientific Reports, 11, Article No. 3986. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, X., et al. (2021) A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients with Breast Cancer. Frontiers in Genetics, 12, Article 606937. [Google Scholar] [CrossRef] [PubMed]